enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene is developing unique genetic medicines for respiratory indications. The company is also evolving its technology to enable applications in several mucosal tissues such as the nasal and genital mucosa as well as the gastrointestinal tract among others.
enGene is supported financially by top-tier institutional investors including Forbion Capital Partners, Fonds de Solidarité FTQ, Pharmstandard International S.A., Lumira Capital and Johnson & Johnson Development Corporation.
|
|
|
51-200 employees
View all enGene employees
|
|
Biotechnology
|
|
7171 Frederick Banting, St-Laurent, Quebec H4S 1Z9, CA
|
|
1999
|
|
Gene Therapy
|
Jason D Hanson is the CEO of enGene. To contact Jason D Hanson email at [email protected] or [email protected].
The decision makers in enGene are Anthony Cheung, Christine Tosone, Christine Tosone, etc. Click to Find enGene decision makers emails.
You can reach out to enGene by visiting their official website and navigating to the 'Contact Us' section. There, you will find a contact form and relevant email addresses for specific inquiries related to their gene therapy services and solutions.
enGene does not publicly provide a detailed staff directory. However, you can find key personnel and their roles on the company's website, typically under the 'About Us' or 'Team' sections, which highlight their expertise in biotechnology and gene therapy.
enGene primarily supports the biotechnology and pharmaceutical industries with its innovative gene therapy solutions. Their proprietary DDX platform is designed for localized delivery of nucleic acid payloads, making it applicable in various therapeutic areas, particularly for mucosal tissues.
Yes, you can request a consultation by contacting enGene through their website. They encourage inquiries from potential partners and clients interested in exploring their non-viral gene therapy technologies and how they can be applied to specific projects.
enGene's DDX platform is highly versatile and can deliver a range of nucleic acid payloads, including DNA, RNA, and various forms of oligonucleotides. This flexibility allows for tailored therapeutic approaches in gene therapy applications.
To stay informed about enGene's latest research and developments, you can subscribe to their newsletter via their website. Additionally, following their official social media channels will provide updates on new projects, publications, and advancements in gene therapy.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.